Académique Documents
Professionnel Documents
Culture Documents
Cardiac
Health, and
Bupropion/
Naltrexone
THE DREAM AND THE
NIGHTMARE
Obesity
One-third of the US population is obese
One-third of the US population is overweight
Associated with a plethora of medical complications
T2DM
CVD
HTN
Depression
CAD
Stroke
Some cancers
Obesity
Obesity-related morbidity leads to increased
hospitalization and greater mortality
Second to smoking as the leading cause of preventable
death
Estimated medical costs of obesity > $100 billion per
annum
Few drugs available due to efficacy and safety concerns
Fen-phen
Obesity Pharmacology
Agents that stimulate POMC signaling
However, direct melanocortin agonists associated with
side effects
Monotherapeutic drug approaches have been modest at
best with a therapeutic plateau
Most likely due to negative feedback from -endorphin
Synergy with two drugs?
Two Drugs
Bupropion (BUP)
DA and NE reuptake inhibitor
Used clinically for depression and smoking cessation
Naltrexone (NAL)
Opioid receptor antagonist
Approved as treatment for opioid and alcohol dependency
Conclusion
BUP + NAL combination treatment worked in synergy to
reduce food intake
Effect likely due to increased POMC firing rates
Next step?
Conclusions
BUP + NAL coadministration leads to a weight-reducing
anorectic effect
Longer term studies needed to show divergence
between BUP + NAL and BUP + P
Phase 3 clinical trial run, but the FDA deferred approval
due to increases in blood pressure and heart rate
Conclusions
It is not possible to assess noninferiority due to early
trial termination
Cardiovascular safety of this treatment remains
uncertain and will require evaluation in a new
adequately powered outcome trial.
My conclusion
Perhaps temperance would be best.